Download PDF
Semin Liver Dis 2014; 34(02): 134-144
DOI: 10.1055/s-0034-1375955
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Clinical Features, Diagnosis, and Natural History of Drug-Induced Liver Injury

Paul H. Hayashi
1   Division of Gastroenterology and Hepatology, University of North Carolina, Chapel Hill, North Carolina
,
Robert J. Fontana
2   Division of Gastroenterology, University of Michigan, Ann Arbor, Michigan
› Author Affiliations
Further Information

Publication History

Publication Date:
31 May 2014 (online)

   Permissions and Reprints

Abstract

Patients with idiosyncratic drug-induced liver injury (DILI) can pose substantial diagnostic, prognostic, and therapeutic challenges to the practicing gastroenterologist. The presentation of DILI may vary from asymptomatic liver enzyme elevation to acute liver failure. Although most DILI resolves following drug discontinuation, up to 20% of patients progress to chronic DILI further challenging the clinicians diagnostic and management skills. Also, some medications can lead to advanced fibrosis, encephalopathy, and portal hypertension without significant elevation in liver enzymes during exposure. Finally, there are no objective tests to definitively diagnose DILI. Although causality assessment instruments are available, none are widely accepted or used in clinical practice. Therefore, the diagnosis of DILI depends on thorough and accurate history taking, follow-up of the patient's clinical course and excluding more common causes of liver injury. In this review, we discuss the variable clinical presentations, course, and diagnostic methods used to establish a diagnosis and prognosis in DILI.

Keywords

hepatotoxicity - diagnostic tools - prognosis - histology - acute - chronic
 

  • References

  • 1 Chalasani N, Fontana RJ, Bonkovsky HL , et al; Drug Induced Liver Injury Network (DILIN). Causes, clinical features, and outcomes from a prospective study of drug-induced liver injury in the United States. Gastroenterology 2008; 135 (6) 1924-1934 , e1–e4
    CrossrefPubMedGoogle Scholar
  • 2 Andrade RJ, Lucena MI, Fernández MC , et al; Spanish Group for the Study of Drug-Induced Liver Disease. Drug-induced liver injury: an analysis of 461 incidences submitted to the Spanish registry over a 10-year period. Gastroenterology 2005; 129 (2) 512-521
    CrossrefPubMedGoogle Scholar
  • 3 Björnsson ES, Bergmann OM, Björnsson HK, Kvaran RB, Olafsson S. Incidence, presentation, and outcomes in patients with drug-induced liver injury in the general population of Iceland. Gastroenterology 2013; 144 (7) 1419-1425 , e1–e3, quiz e19–e20
    CrossrefPubMedGoogle Scholar
  • 4 Sgro C, Clinard F, Ouazir K , et al. Incidence of drug-induced hepatic injuries: a French population-based study. Hepatology 2002; 36 (2) 451-455
    CrossrefPubMedGoogle Scholar
  • 5 Ostapowicz G, Fontana RJ, Schiødt FV , et al; U.S. Acute Liver Failure Study Group. Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann Intern Med 2002; 137 (12) 947-954
    CrossrefPubMedGoogle Scholar
  • 6 Watkins PB. Drug safety sciences and the bottleneck in drug development. Clin Pharmacol Ther 2011; 89 (6) 788-790
    CrossrefPubMedGoogle Scholar
  • 7 Temple R. Hy's law: predicting serious hepatotoxicity. Pharmacoepidemiol Drug Saf 2006; 15 (4) 241-243
    CrossrefPubMedGoogle Scholar
  • 8 Björnsson E, Olsson R. Outcome and prognostic markers in severe drug-induced liver disease. Hepatology 2005; 42 (2) 481-489
    CrossrefPubMedGoogle Scholar
  • 9 Polson J, Lee WM ; American Association for the Study of Liver Disease. AASLD position paper: the management of acute liver failure. Hepatology 2005; 41 (5) 1179-1197
    CrossrefPubMedGoogle Scholar
  • 10 Lee WM. Drug-induced acute liver failure. Clin Liver Dis 2013; 17 (4) 575-586 , viii
    CrossrefPubMedGoogle Scholar
  • 11 Mindikoglu AL, Magder LS, Regev A. Outcome of liver transplantation for drug-induced acute liver failure in the United States: analysis of the United Network for Organ Sharing database. Liver Transpl 2009; 15 (7) 719-729
    CrossrefPubMedGoogle Scholar
  • 12 Danielides IC, Constantoulakis M, Daikos GK. Hepatitis on high dose isoniazid: reintroduction of the drug in severe tuberculous meningitis. Am J Gastroenterol 1983; 78 (6) 378-380
    PubMedGoogle Scholar
  • 13 LiverTox. Isoniazid. Available at: http://livertox.nlm.nih.gov/Isoniazid.htm . Accessed June 6, 2013
    PubMedGoogle Scholar
  • 14 Black M, Mitchell JR, Zimmerman HJ, Ishak KG, Epler GR. Isoniazid-associated hepatitis in 114 patients. Gastroenterology 1975; 69 (2) 289-302
    PubMedGoogle Scholar
  • 15 Harrill AH, Roach J, Fier I , et al. The effects of heparins on the liver: application of mechanistic serum biomarkers in a randomized study in healthy volunteers. Clin Pharmacol Ther 2012; 92 (2) 214-220
    CrossrefPubMedGoogle Scholar
  • 16 LiverTox. Heparins. Available at: http://livertox.nlm.nih.gov/Heparin.htm . Accessed October 4, 2013
    PubMedGoogle Scholar
  • 17 McDonald C, Uy J, Hu W , et al. Clinical significance of hyperbilirubinemia among HIV-1-infected patients treated with atazanavir/ritonavir through 96 weeks in the CASTLE study. AIDS Patient Care STDS 2012; 26 (5) 259-264
    CrossrefPubMedGoogle Scholar
  • 18 Grant L, Lee WL, Rockey DC. Trimethoprim/Sulfamethoxazole hepatotoxicity: Analysis of 31 cases. Hepatology 2013; 58 (4, Suppl) 382A
    PubMedGoogle Scholar
  • 19 Blumenthal KG, Patil SU, Long AA. The importance of vancomycin in drug rash with eosinophilia and systemic symptoms (DRESS) syndrome. Allergy Asthma Proc 2012; 33 (2) 165-171
    CrossrefPubMedGoogle Scholar
  • 20 Fleming P, Marik PE. The DRESS syndrome: the great clinical mimicker. Pharmacotherapy 2011; 31 (3) 332
    CrossrefPubMedGoogle Scholar
  • 21 Björnsson E. Hepatotoxicity associated with antiepileptic drugs. Acta Neurol Scand 2008; 118 (5) 281-290
    PubMedGoogle Scholar
  • 22 Björnsson E, Talwalkar J, Treeprasertsuk S , et al. Drug-induced autoimmune hepatitis: clinical characteristics and prognosis. Hepatology 2010; 51 (6) 2040-2048
    CrossrefPubMedGoogle Scholar
  • 23 Ghabril M, Bonkovsky HL, Kum C , et al; US Drug-Induced Liver Injury Network. Liver injury from tumor necrosis factor-α antagonists: analysis of thirty-four cases. Clin Gastroenterol Hepatol 2013; 11 (5) 558 , e3
    CrossrefPubMedGoogle Scholar
  • 24 Zimmerman HJ. Oncotherapeutic and immunosuppressive agents. In: Zimmerman HJ. Hepatotoxicity: the adverse effects of drugs and other chemicals on the liver. 2nd ed. Philadelphia: Lippincott Williams & Wilkins; 1999: 681-687
    Google Scholar
  • 25 Kalb RE, Strober B, Weinstein G, Lebwohl M. Methotrexate and psoriasis: 2009 National Psoriasis Foundation Consensus Conference. J Am Acad Dermatol 2009; 60 (5) 824-837
    CrossrefPubMedGoogle Scholar
  • 26 Saag KG, Teng GG, Patkar NM , et al; American College of Rheumatology. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum 2008; 59 (6) 762-784
    CrossrefPubMedGoogle Scholar
  • 27 Kremer JM, Alarcón GS, Lightfoot Jr RW , et al; American College of Rheumatology. Methotrexate for rheumatoid arthritis. Suggested guidelines for monitoring liver toxicity. Arthritis Rheum 1994; 37 (3) 316-328
    CrossrefPubMedGoogle Scholar
  • 28 LiverTox Valproate. Available at: http://livertox.nlm.nih.gov/Valproate.htm . Accessed November 5, 2013
    PubMed
  • 29 Zimmerman HJ. Psychotropic and anticonvulsant agents. In: Zimmerman HJ. Hepatotoxicity: the adverse effects of drugs and other chemicals on the liver. 2nd ed. Philadelphia: Lippincott Williams & Wilkins; 1999: 504-508
    Google Scholar
  • 30 Dealberto MJ. Valproate-induced hyperammonaemic encephalopathy: review of 14 cases in the psychiatric setting. Int Clin Psychopharmacol 2007; 22 (6) 330-337
    CrossrefPubMedGoogle Scholar
  • 31 Uusimaa J, Hinttala R, Rantala H , et al. Homozygous W748S mutation in the POLG1 gene in patients with juvenile-onset Alpers syndrome and status epilepticus. Epilepsia 2008; 49 (6) 1038-1045
    CrossrefPubMedGoogle Scholar
  • 32 Angitapalli R, Litwin AM, Kumar PR , et al. Adjuvant FOLFOX chemotherapy and splenomegaly in patients with stages II-III colorectal cancer. Oncology 2009; 76 (5) 363-368
    CrossrefPubMedGoogle Scholar
  • 33 Slade JH, Alattar ML, Fogelman DR , et al. Portal hypertension associated with oxaliplatin administration: clinical manifestations of hepatic sinusoidal injury. Clin Colorectal Cancer 2009; 8 (4) 225-230
    CrossrefPubMedGoogle Scholar
  • 34 DeLeve LD, Valla DC, Garcia-Tsao G ; American Association for the Study Liver Diseases. Vascular disorders of the liver. Hepatology 2009; 49 (5) 1729-1764
    CrossrefPubMedGoogle Scholar
  • 35 McDonald GB, Hinds MS, Fisher LD , et al. Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation: a cohort study of 355 patients. Ann Intern Med 1993; 118 (4) 255-267
    CrossrefPubMedGoogle Scholar
  • 36 Jones RJ, Lee KS, Beschorner WE , et al. Venoocclusive disease of the liver following bone marrow transplantation. Transplantation 1987; 44 (6) 778-783
    CrossrefPubMedGoogle Scholar
  • 37 Danan G, Benichou C. Causality assessment of adverse reactions to drugs—I. A novel method based on the conclusions of international consensus meetings: application to drug-induced liver injuries. J Clin Epidemiol 1993; 46 (11) 1323-1330
    CrossrefPubMedGoogle Scholar
  • 38 Benichou C, Danan G, Flahault A. Causality assessment of adverse reactions to drugs—II. An original model for validation of drug causality assessment methods: case reports with positive rechallenge. J Clin Epidemiol 1993; 46 (11) 1331-1336
    CrossrefPubMedGoogle Scholar
  • 39 Maria VA, Victorino RM. Development and validation of a clinical scale for the diagnosis of drug-induced hepatitis. Hepatology 1997; 26 (3) 664-669
    CrossrefPubMedGoogle Scholar
  • 40 Agarwal VK, McHutchison JG, Hoofnagle JH ; Drug-Induced Liver Injury Network. Important elements for the diagnosis of drug-induced liver injury. Clin Gastroenterol Hepatol 2010; 8 (5) 463-470
    CrossrefPubMedGoogle Scholar
  • 41 Fontana RJ, Seeff LB, Andrade RJ , et al. Standardization of nomenclature and causality assessment in drug-induced liver injury: summary of a clinical research workshop. Hepatology 2010; 52 (2) 730-742
    CrossrefPubMedGoogle Scholar
  • 42 Barritt IV AS, Lee J, Hayashi PH. Detective work in drug-induced liver injury: sometimes it is all about interviewing the right witness. Clin Gastroenterol Hepatol 2010; 8 (7) 635-637
    CrossrefPubMedGoogle Scholar
  • 43 Bailey RL, Gahche JJ, Lentino CV , et al. Dietary supplement use in the United States, 2003-2006. J Nutr 2011; 141 (2) 261-266
    CrossrefPubMedGoogle Scholar
  • 44 Navarro VJ, Barnhart HX, Bonkovsky HL , et al. The rising burden of herbal and dietary supplement induced hepatotoxicity in the U.S.A. Hepatology 2013; 58 (4, suppl): 264A
    PubMedGoogle Scholar
  • 45 Navarro VJ, Bonkovsky HL, Hwang SI, Vega M, Barnhart H, Serrano J. Catechins in dietary supplements and hepatotoxicity. Dig Dis Sci 2013; 58 (9) 2682-2690
    CrossrefPubMedGoogle Scholar
  • 46 Means B, Swan GE, Jobe JB, Esposito JL. An alternative approach to obtaining personal history data. In: Biemeer PP, Groves RM, Lyberg LE, Mathiowetz NA, Sudman S, , eds. Measurement of Errors in Surveys. New York: John Wiley and Sons; 1991: 167-183
    Google Scholar
  • 47 Friedenreich CM. Improving long-term recall in epidemiologic studies. Epidemiology 1994; 5 (1) 1-4
    CrossrefPubMedGoogle Scholar
  • 48 Bénichou C. Criteria of drug-induced liver disorders. Report of an international consensus meeting. J Hepatol 1990; 11 (2) 272-276
    CrossrefPubMedGoogle Scholar
  • 49 Lammert C, Einarsson S, Saha C, Niklasson A, Bjornsson E, Chalasani N. Relationship between daily dose of oral medications and idiosyncratic drug-induced liver injury: search for signals. Hepatology 2008; 47 (6) 2003-2009
    CrossrefPubMedGoogle Scholar
  • 50 Chen M, Borlak J, Tong W. High lipophilicity and high daily dose of oral medications are associated with significant risk for drug-induced liver injury. Hepatology 2013; 58 (1) 388-396
    PubMedGoogle Scholar
  • 51 Food and Drug Administration. Summary of NDA Approvals & Receipts, 1938 to the present. Available at: http://www.fda.gov/AboutFDA/WhatWeDo/History/ProductRegulation/SummaryofNDAApprovalsReceipts1938tothepresent/default.htm . Accessed March 31, 2013
    PubMed
  • 52 National Library of Medicine. LiverTox. Available at: http://www.LiverTox.nih.gov . Accessed March 31, 2013
    PubMedGoogle Scholar
  • 53 Hoofnagle JH, Serrano J, Knoben JE, Navarro VJ. LiverTox: a website on drug-induced liver injury. Hepatology 2013; 57 (3) 873-874
    CrossrefPubMedGoogle Scholar
  • 54 Yeoman AD, Westbrook RH, Al-Chalabi T , et al. Diagnostic value and utility of the simplified International Autoimmune Hepatitis Group (IAIHG) criteria in acute and chronic liver disease. Hepatology 2009; 50 (2) 538-545
    PubMedGoogle Scholar
  • 55 Fernández-Ruiz M, Muñoz-Codoceo C, López-Medrano F , et al. Cytomegalovirus myopericarditis and hepatitis in an immunocompetent adult: successful treatment with oral valganciclovir. Intern Med 2008; 47 (22) 1963-1966
    CrossrefPubMedGoogle Scholar
  • 56 Cohen JI, Corey GR. Cytomegalovirus infection in the normal host. Medicine (Baltimore) 1985; 64 (2) 100-114
    PubMedGoogle Scholar
  • 57 Gupta E, Bhatia V, Choudhary A, Rastogi A, Gupta NL. Epstein-Barr virus associated acute hepatitis with cross-reacting antibodies to other herpes viruses in immunocompetent patients: report of two cases. J Med Virol 2013; 85 (3) 519-523
    CrossrefPubMedGoogle Scholar
  • 58 Riviere Marcelin J, Jones JM, Costello BA. 41-year-old woman with fever, neutropenia, and elevated transaminase levels. Mayo Clin Proc 2013; 88 (1) 113-116
    CrossrefPubMedGoogle Scholar
  • 59 Ichai P, Roque Afonso AM, Sebagh M , et al. Herpes simplex virus-associated acute liver failure: a difficult diagnosis with a poor prognosis. Liver Transpl 2005; 11 (12) 1550-1555
    CrossrefPubMedGoogle Scholar
  • 60 Dalton HR, Fellows HJ, Stableforth W , et al. The role of hepatitis E virus testing in drug-induced liver injury. Aliment Pharmacol Ther 2007; 26 (10) 1429-1435
    CrossrefPubMedGoogle Scholar
  • 61 Davern TJ, Chalasani N, Fontana RJ , et al; Drug-Induced Liver Injury Network (DILIN). Acute hepatitis E infection accounts for some cases of suspected drug-induced liver injury. Gastroenterology 2011; 141 (5) 1665-1672 , e1–e9
    CrossrefPubMedGoogle Scholar
  • 62 Hoofnagle JH, Nelson KE, Purcell RH. Hepatitis E. N Engl J Med 2012; 367 (13) 1237-1244
    CrossrefPubMedGoogle Scholar
  • 63 European Association for Study of Liver. EASL Clinical Practice Guidelines: Wilson's disease. J Hepatol 2012; 56 (3) 671-685
    CrossrefPubMedGoogle Scholar
  • 64 Dowling D. Screening for Wilson's disease in acute liver failure: a comparison of currently available diagnostic tests. Hepatology 2009; 50 (1) 329
    PubMedGoogle Scholar
  • 65 Maple JT, Ben-Menachem T, Anderson MA , et al; ASGE Standards of Practice Committee. The role of endoscopy in the evaluation of suspected choledocholithiasis. Gastrointest Endosc 2010; 71 (1) 1-9
    CrossrefPubMedGoogle Scholar
  • 66 Yang MH, Chen TH, Wang SE , et al. Biochemical predictors for absence of common bile duct stones in patients undergoing laparoscopic cholecystectomy. Surg Endosc 2008; 22 (7) 1620-1624
    CrossrefPubMedGoogle Scholar
  • 67 Lindor KD, Gershwin ME, Poupon R, Kaplan M, Bergasa NV, Heathcote EJ ; American Association for Study of Liver Diseases. Primary biliary cirrhosis. Hepatology 2009; 50 (1) 291-308
    CrossrefPubMedGoogle Scholar
  • 68 Chapman R, Fevery J, Kalloo A , et al; American Association for the Study of Liver Diseases. Diagnosis and management of primary sclerosing cholangitis. Hepatology 2010; 51 (2) 660-678
    CrossrefPubMedGoogle Scholar
  • 69 Farrell GC. Drug-Induced Liver Disease. Edinburgh, UK: Churchill Livingstone; 1994
    Google Scholar
  • 70 Lewis JH, Kleiner DE. Hepatic injury due to drugs, chemicals and toxins. In: Burt AD, Portmann BC, Ferrell LD, , eds. MacSween's Pathology of the Liver. Philadelphia, PA: Elsevier; 2007
    Google Scholar
  • 71 Kleiner DE, Chalasani NP, Lee WM , et al; Drug-Induced Liver Injury Network (DILIN). Hepatic histological findings in suspected drug-induced liver injury: systematic evaluation and clinical associations. Hepatology 2014; 59 (2) 661-670
    CrossrefPubMedGoogle Scholar
  • 72 Björnsson E, Kalaitzakis E, Olsson R. The impact of eosinophilia and hepatic necrosis on prognosis in patients with drug-induced liver injury. Aliment Pharmacol Ther 2007; 25 (12) 1411-1421
    CrossrefPubMedGoogle Scholar
  • 73 Katoonizadeh A, Nevens F, Verslype C, Pirenne J, Roskams T. Liver regeneration in acute severe liver impairment: a clinicopathological correlation study. Liver Int 2006; 26 (10) 1225-1233
    CrossrefPubMedGoogle Scholar
  • 74 Hennes EM, Zeniya M, Czaja AJ , et al; International Autoimmune Hepatitis Group. Simplified criteria for the diagnosis of autoimmune hepatitis. Hepatology 2008; 48 (1) 169-176
    CrossrefPubMedGoogle Scholar
  • 75 Czaja AJ. Corticosteroids or not in severe acute or fulminant autoimmune hepatitis: therapeutic brinksmanship and the point beyond salvation. Liver Transpl 2007; 13 (7) 953-955
    CrossrefPubMedGoogle Scholar
  • 76 Ichai P, Duclos-Vallée JC, Guettier C , et al. Usefulness of corticosteroids for the treatment of severe and fulminant forms of autoimmune hepatitis. Liver Transpl 2007; 13 (7) 996-1003
    CrossrefPubMedGoogle Scholar
  • 77 Berends MA, van Oijen MG, Snoek J , et al. Reliability of the Roenigk classification of liver damage after methotrexate treatment for psoriasis: a clinicopathologic study of 160 liver biopsy specimens. Arch Dermatol 2007; 143 (12) 1515-1519
    PubMedGoogle Scholar
  • 78 Rochon J, Protiva P, Seeff LB , et al; Drug-Induced Liver Injury Network (DILIN). Reliability of the Roussel Uclaf Causality Assessment Method for assessing causality in drug-induced liver injury. Hepatology 2008; 48 (4) 1175-1183
    CrossrefPubMedGoogle Scholar
  • 79 Rockey DC, Seeff LB, Rochon J , et al; US Drug-Induced Liver Injury Network. Causality assessment in drug-induced liver injury using a structured expert opinion process: comparison to the Roussel-Uclaf causality assessment method. Hepatology 2010; 51 (6) 2117-2126
    CrossrefPubMedGoogle Scholar
  • 80 Fontana RJ, Watkins PB, Bonkovsky HL , et al; DILIN Study Group. Drug-Induced Liver Injury Network (DILIN) prospective study: rationale, design and conduct. Drug Saf 2009; 32 (1) 55-68
    CrossrefPubMedGoogle Scholar
  • 81 Kaplowitz N. Causality assessment versus guilt-by-association in drug hepatotoxicity. Hepatology 2001; 33 (1) 308-310
    CrossrefPubMedGoogle Scholar
  • 82 Aithal PG, Day CP. The natural history of histologically proved drug induced liver disease. Gut 1999; 44 (5) 731-735
    CrossrefPubMedGoogle Scholar
  • 83 Björnsson E, Davidsdottir L. The long-term follow-up after idiosyncratic drug-induced liver injury with jaundice. J Hepatol 2009; 50 (3) 511-517
    CrossrefPubMedGoogle Scholar
  • 84 Fontana RJ, Hayashi PH, Gu J , et al. Idiosyncratic drug induced liver injury is associated with substantial morbidity and mortality within 6 months from onset.. Gastroenterology 2014; 56 ; Mar 26 [Epub ahead of print]
    PubMedGoogle Scholar